More recently, the combination of the anti-PD-L1monoclonal antibody, atezolizumab, with combined BRAF and MEK inhibition (vemurafenib + cobimetinib) significantly prolonged progression-free survival compared with the combination of vemurafenib and cobimetinib, plus placebo in patients with advanced unresectable BRAF mutation–positive cutaneous melanoma.19 This evidence concerns the gene MAP2K7 and cutaneous melanoma.